This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Curtiss, C. Articles by Franciosa, J. A. Search for Related Content PubMed PubMed Citation Articles by Curtiss, C. Articles by Franciosa, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure

Circulation, Vol 58, 763-770, Copyright © 1978 by American Heart Association

ARTICLES

Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure

C Curtiss, JN Cohn, T Vrobel and JA Franciosa

In 15 patients with severe chronic left ventricular failure, plasma renin activity (PRA) ranged widely, from 0.2--39 ng/ml/hr. The level of PRA was unrelated to cardiac output (CO) or pulmonary artery wedge pressure (PWP), but was slightly negatively correlated with mean arterial pressure (MAP) (r = -0.45) and systemic vascular resistance (SVR) (r = -0.40). After infusion of the angiotensin converting enzyme inhibitor teprotide (SQ 20,881) PWP fell from 26.3 +/- 1.3 (SEM) to 20.3 +/- 1.4 mm Hg (P less than 0.001), CO rose from 3.94 +/- 0.23 to 4.75 +/- 0.31 l/min (P less than 0.001), MAP fell from 87.5 +/- 3.8 to 77.9 +/- 4.1 mm Hg (P less than 0.001) and SVR from 1619 +/- 148 to 1252 +/- 137 dyne-sec-cm-5 (P less than 0.001). The fall in MAP and in SVR was significantly correlated with control PRA (r = 0.68 and r = 0.58, respectively). When subjects were divided on the basis of control PRA the hemodynamic response to teprotide was greatest in the high renin group. PRA rose after teprotide (8.7 +/- 3.4 to 37.9 +/- 7.7 ng/ml/hr, P less than 0.05) but plasma norepinephrine fell (619.1 +/- 103.6 to 449.7 +/- 75.7, P less than 0.05). The renin-angiotensin system thus appears to have an important role in the elevated SVR in some patients with heart failure. Chronic inhibition of converting enzyme should be explored as a possible therapeutic approach.

This article has been cited by other articles:

				S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure Heart, May 1, 2006; 92(5): 625 - 630. [Abstract] [Full Text] [PDF]

				D. O. Okonko, D. J. Van Veldhuisen, P. A. Poole-Wilson, and S. D. Anker Anaemia of chronic disease in chronic heart failure: the emerging evidence Eur. Heart J., November 1, 2005; 26(21): 2213 - 2214. [Full Text] [PDF]

				T. Kishi, Y. Hirooka, A. Masumoto, K. Ito, Y. Kimura, K. Inokuchi, T. Tagawa, H. Shimokawa, A. Takeshita, and K. Sunagawa Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients With Heart Failure Circulation, May 31, 2005; 111(21): 2741 - 2747. [Abstract] [Full Text] [PDF]

				J. N. Cohn Clinical Research: Whose Agenda Is It? Circulation, May 18, 2004; 109(19): 2256 - 2262. [Full Text] [PDF]

				R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734. [Abstract] [Full Text] [PDF]

				S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure J. Nucl. Med., June 1, 2003; 44(6): 884 - 890. [Abstract] [Full Text] [PDF]

				H. Gavras and H. R. Brunner Role of Angiotensin and Its Inhibition in Hypertension, Ischemic Heart Disease, and Heart Failure Hypertension, February 1, 2001; 37(2): 342 - 345. [Abstract] [Full Text] [PDF]

				J. N. Cohn Left Ventricle and Arteries : Structure, Function, Hormones, and Disease Hypertension, February 1, 2001; 37(2): 346 - 349. [Abstract] [Full Text] [PDF]

				T. Hisaoka, M. Yano, T. Ohkusa, M. Suetsugu, K. Ono, M. Kohno, J. Yamada, S. Kobayashi, M. Kohno, and M. Matsuzaki Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure Cardiovasc Res, February 1, 2001; 49(2): 319 - 329. [Abstract] [Full Text] [PDF]

				E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]

				H. N. Sabbah Apoptotic cell death in heart failure Cardiovasc Res, February 1, 2000; 45(3): 704 - 712. [Full Text] [PDF]

				G. S. Francis ACE Inhibition in Cardiovascular Disease N. Engl. J. Med., January 20, 2000; 342(3): 201 - 202. [Full Text]

				L. Baruch, I. Anand, I. S. Cohen, S. Ziesche, D. Judd, and J. N. Cohn Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure Circulation, May 25, 1999; 99(20): 2658 - 2664. [Abstract] [Full Text] [PDF]

				N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]

				J. N. Cohn The Management of Chronic Heart Failure N. Engl. J. Med., August 15, 1996; 335(7): 490 - 498. [Full Text] [PDF]

				J. N. Cohn Is There a Role for Endothelin in the Natural History of Heart Failure? Circulation, August 15, 1996; 94(4): 604 - 606. [Full Text]

				C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]

				G. M. Eaton, R. J. Cody, E. Nunziata, and P. F. Binkley Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure Circulation, August 1, 1995; 92(3): 555 - 561. [Abstract] [Full Text]

				J. N. Cohn Structural Basis for Heart Failure : Ventricular Remodeling and Its Pharmacological Inhibition Circulation, May 15, 1995; 91(10): 2504 - 2507. [Full Text]

				B. Greenberg, M. A. Quinones, C. Koilpillai, M. Limacher, D. Shindler, C. Benedict, and B. Shelton Effects of Long-term Enalapril Therapy on Cardiac Structure and Function in Patients With Left Ventricular Dysfunction : Results of the SOLVD Echocardiography Substudy Circulation, May 15, 1995; 91(10): 2573 - 2581. [Abstract] [Full Text]

				A. M. Feldman Can We Alter Survival in Patients With Congestive Heart Failure? JAMA, April 8, 1992; 267(14): 1956 - 1961. [Abstract] [PDF]

				J. R. Oster and B. J. Materson Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors Arch Intern Med, April 1, 1992; 152(4): 704 - 710. [Abstract] [PDF]

				M. A. Munger, S. F. Gardner, and R. C. Jarvis Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331. [Abstract] [PDF]

				G. S. FRANCIS, S. R. GOLDSMITH, T. B. LEVINE, M. T. OLIVARI, and J. N. COHN The Neurohumoral Axis in Congestive Heart Failure Ann Intern Med, September 1, 1984; 101(3): 370 - 377. [Abstract] [PDF]